Merit Medical Systems Inc. filings document operating and financial results, Regulation FD disclosures and material events for a medical-device manufacturer serving interventional, diagnostic and therapeutic markets. Recent Form 8-K reports cover quarterly and annual results, conference-call materials, historical revenue information under the Foundational and Therapeutic product categories, and product-related updates.
The company’s proxy materials describe board composition, governance practices, executive compensation and shareholder voting matters. Other filed event reports address board-leadership changes, completed product-technology acquisitions, capital-structure disclosure categories and clinical or regulatory disclosures tied to Merit’s device portfolio.
MMSI submitted a Form 144 notice to offer 5,000 Common shares for sale, listed with a 05/07/2026 date. The filing lists two restricted stock lots of 2,914 shares dated 06/17/2022 and 2,086 shares dated 05/18/2024.
MERIT MEDICAL SYSTEMS INC Chief Financial Officer and Treasurer Raul Parra Jr. reported an open-market purchase of 1,500 shares of common stock at $61.01 per share on May 6, 2026. After this transaction, he directly holds 58,843 shares of common stock.
He also has an indirect interest in 2,699 shares held through a 401(k) Plan, representing plan holdings as of May 5, 2026. In addition, he holds non-qualified stock options for 13,576 underlying shares at an exercise price of $70.58 expiring on February 28, 2030, and options for 9,070 underlying shares at $65.03 expiring on February 28, 2029.
MERIT MEDICAL SYSTEMS INC executive Michel J. Voigt, the Chief Human Resources Officer, reported an open-market purchase of company stock through a retirement plan. He bought 2,250 shares of common stock at $60.65 per share, held indirectly via a 401(k) Plan, bringing those plan holdings to 2,265 shares as of the reported date.
Voigt also reports 46,127 shares of common stock held directly. In addition, he holds non-qualified stock options covering 11,076 shares at $70.58, 4,046 shares at $65.03, and 2,420 shares at $56.25, which become exercisable in 25% annual installments and expire between 2028 and 2030.
Merit Medical Systems delivered higher profitability in the quarter ended March 31, 2026. Net sales rose to $381.9 million from $355.4 million, a 7.5% increase, with growth in both foundational and therapeutic product categories and across domestic and international markets. Gross margin held steady at 48.4%, while operating income increased to $44.2 million. Net income improved to $41.0 million, or $0.68 diluted EPS, compared with $30.1 million, or $0.49 diluted EPS, a meaningful step-up in earnings. Cash, cash equivalents and restricted cash reached $490.2 million, and the company reported strong liquidity with over $697 million of additional borrowing capacity on its revolving credit facility. During the quarter, Merit completed the $28 million sale of its DualCap product line, generating a $12.5 million pre-tax gain, and later announced a $140 million acquisition of View Point Medical to expand its tissue localization technologies.
Merit Medical Systems, Inc. reported solid first quarter 2026 results, with net sales of $381.9 million, up 7.5% from $355.4 million a year earlier. GAAP diluted earnings per share were $0.68 versus $0.49, and non-GAAP EPS rose 9% to $0.94.
GAAP gross margin held at 48.4%, while non-GAAP operating margin improved to 19.7% from 19.3%. Free cash flow increased 26% to $24.7 million. Revenue by product category grew 6% in Foundational and 10% in Therapeutic on a reported basis.
For full-year 2026, Merit guides total revenue to $1.612–$1.634 billion, implying 6.3–7.8% GAAP growth, and maintains non-GAAP EPS guidance of $4.01–$4.15, or 5–8% growth. Updated guidance incorporates the April 1 acquisition of View Point Medical’s OneMark System, expected to add $2–$4 million of 2026 revenue and dilute prior non-GAAP EPS guidance by about $0.05.
Merit Medical Systems Inc Schedule 13G: Vanguard Capital Management reports beneficial ownership of 3,109,720 shares of Common Stock, representing 5.23% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over all 3,109,720 shares and sole voting power over 453,557 shares. The disclosure notes holdings include shares held for Vanguard funds and managed accounts and names related Vanguard affiliates.
Vanguard Portfolio Management LLC reported beneficial ownership of 3,571,916 shares of Merit Medical Systems Inc. Common Stock (CUSIP 589889104), representing 6.01% of the class as disclosed on the Schedule 13G. The filing shows sole voting power for 48,828 shares and sole dispositive power for 3,571,916 shares.
Merit Medical Systems, Inc. furnished updated historical revenue breakdowns to align with its new foundational and therapeutic product categories. The data covers the years ended December 31, 2025, 2024, 2023 and 2022, and quarterly results for each three‑month period from March 31, 2024 through December 31, 2025.
For 2025, revenue was $1,515,906 thousand, including $1,028,540 thousand from foundational products and $487,366 thousand from therapeutic products. The company also provided 2025 and 2024 quarterly revenues by category and detailed platform-level revenues within each category, such as Access, OEM, Cardiac Therapies and Oncology.
The company states this information is supplemental, does not revise or restate previously reported consolidated financial statements, and is furnished under Regulation FD rather than filed for liability purposes or automatic incorporation into other Securities Act or Exchange Act filings.
MERIT MEDICAL SYSTEMS INC director Fred P. Lampropoulos filed a Form 4 reporting his status as an insider. The summarized data show no reported purchases, sales, exercises, gifts, or other equity transactions in the covered period, and no derivative positions listed.
Merit Medical Systems has acquired View Point Medical in a merger, making View Point a wholly owned subsidiary and adding its OneMark Detection Imaging System and OneMark Tissue Markers to Merit’s therapeutic oncology portfolio. Total consideration, including assumed liabilities, is about $140 million, with $90 million paid in cash at closing and two deferred payments of $25 million each due by the first and second anniversaries of closing.
From April 1 through year-end 2026, the deal is projected to add $2–$4 million of revenue and dilute previously forecast non-GAAP earnings per share by about $0.05, including roughly $2.0 million of lower interest income on cash used. For 2027, revenue contribution is projected at $14–$16 million, with at least 20% annual sales growth, about 70% non-GAAP gross margins and accretion to non-GAAP operating margins, while remaining dilutive to GAAP earnings in 2026–2027 and accretive thereafter.